On Demand OCD and Anxiety Lecture Series: Obsessive-Compulsive Disorder: Standard of Care and Innovative Treatment Strategies
This presentation was originally reviewed on May 13, 2022, and broadcast live online on May 13, 2022, from 2:45 PM - 4:15 PM ET.
The views and opinions expressed by this presenter in this lecture are their own, and do not represent the views of Sheppard Pratt.
Obsessive compulsive disorder is reasonably common, affecting about 1 person in 40 over the course of a lifetime, but often goes undiagnosed and inadequately treated. This presentation will first provide an overview of the clinical presentation of OCD, with a focus on the complexity and heterogeneity that is often encountered. We will then review well proven, standard-of-care treatments, with a brief overview of well-established cognitive-behavioral approaches and a more detailed discussion of standard pharmacotherapy. Unfortunately, even optimal deployment of evidence-based treatments leaves about a third of patients with little meaningful improvement; many who do improve are left with troubling residual symptoms. There is therefore an urgent need for new treatments for refractory disease. The final portion of the talk will describe several novel treatment strategies being investigated in the speaker’s research group, including novel medications, new psychotherapies, and brain stimulation.
This activity is intended for physicians, nurses, psychologists, social workers, counselors, and other mental health professionals.
After this lecture, registrants will be able to:
- Recognize the core symptoms of OCD and differentiate them from frequently comorbid anxiety and mood symptomatology.
- Explain standard pharmacological strategies for the treatment of OCD.
- Discuss the use of glutamate-modulating drugs in the treatment of OCD that is refractory to first-and second-line treatment, recognizing that the evidence supporting these medications remains limited and better-proven treatments should always be tried first.
There is no commercial support for this activity.
About the speaker
Christopher Pittenger, MD, PhD, is Mears & Jameson Professor of Psychiatry and Professor in the Child Study Center, Deputy Chair for Translational Research in Psychiatry, Director of the Yale OCD Research Clinic, and Director of the Neuroscience Research Training Program (NRTP) and the Clinical Neuroscience Research Unit at Yale University. He completed his MD and PhD degrees at Columbia University and his residency in adult psychiatry at Yale. His research focuses on the pathophysiology of obsessive-compulsive disorder (OCD), Tourette syndrome, and related conditions, and on harnessing new insights to develop novel strategies for diagnosis, prevention, and treatment; his work incorporates genetics, biochemistry, mechanistic studies in animal models, investigations of neuro-immune interactions, human neuroimaging and quantitative behavioral studies, psychotherapy and neurofeedback, testing novel pharmacological strategies in patients with refractory disease, and brain stimulation.
His clinical expertise in the diagnosis and treatment of difficult cases of OCD is widely recognized; in 2017 he authored a comprehensive textbook on OCD with Oxford University Press. He leads the scientific programming and grant selection committee at the International OCD Foundation (IOCDF) and sits on the Scientific, Clinical, and/or Educational Advisory Boards of the IOCDF, the PANDAS Network, the Neuroimmune Foundation, the UCSF and Mt. Sinai School of Medicine Physician-Training Programs, and the Stanford PANS Clinic. As Director of the NRTP he leads Yale’s educational efforts for the training of physician-scientists in psychiatry and has mentored a generation of young investigators. Dr. Pittenger’s work has been recognized and supported by the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the International OCD Foundation, The Tourette’s Association of American, the Brain and Behavior Research Foundation, the Doris Duke Charitable Foundation, the Simons Foundation Autism Research Initiative, and numerous other charitable foundations and industry partners.
Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.
Christopher Pittenger, MD, PhD, reports he will discuss off-label use for Riluzole, Memantine, Ketamine, and the investigational use of Tririluzole in this presentation. He also reports the following relationships with financial interest: Biohaven Pharmaceuticals - Consultant; Grant Support; Ceruvia Biosciences - Consultant.; Transcend Therapeutics - Grant Support; Freedom Biosciences - Consultant; Usona Institute - Grant Support. No products or services used on patients will be discussed during this presentation. This presentation and all the content materials were reviewed to mitigate any identified conflicts of interest.
Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Jon Hershfield, MFT, Todd Peters, MD, Deepak Prabhakar, MD, Briana Riemer, MD, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Bruce Boxer, PhD, MBA, MA, MSN, RN, NPD-BC, NEA-BC, MCHES, CPHQ, Stacey Garnett, RN, MSN, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.
Physician Statement: Sheppard Pratt is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Statement: Sheppard Pratt is approved as a provider of nursing continuing professional development by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity provides 1.5 contact hours for nurses.
Psychologist Statement: Sheppard Pratt is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt designates this educational activity for a maximum of 1.5 contact hours for Psychologists.
Social Worker Statement: Sheppard Pratt is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.5 contact hours in Category II credits for Social Workers.
Counselor Statement: Sheppard Pratt has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098. Programs that do not qualify for NBCC credit are clearly identified. Sheppard Pratt is solely responsible for all aspects of the program. This activity is available for 1.5 NBCC clock hours.
- 1.50 ACEP NBCC clock hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Category II credits for Social Workers
- 1.50 Psychologists
- 1.50 MNA Contact Hours for Nurses
- 1.50 Participation
ON DEMAND WEBINAR: FOR BEST RESULTS WATCH USING GOOGLE CHROME
OCD & Anxiety Lecture Series: Obsessive-Compulsive Disorder: Standard of Care and Innovative Treatment Strategies
Christopher Pittenger, MD, PhD
Mears & Jameson Professor of Psychiatry, and Professor in the Yale Child Study Center
Deputy Chair for Translational Research, Department of Psychiatry
Director, Clinical Neuroscience Research Unit
Director, Yale OCD Research Clinic
Director, Neuroscience Research Training Program
Director, Yale Program for Psychedelic Science
Yale University School of Medicine
New Haven, CT
Originally reviewed May 13,2022.
Originally broadcast live May 13,2022 , from 2:45 pm - 4:15 pm ET
Enduring Activity Credit Expiration Date: Monday, June 12, 2024.
Activity Time: Ninety-minute recorded webinar lecture with a 15-minute evaluation process. Total Time: 1:45
TO EARN CONTINUING EDUCATION CREDIT FOR YOUR ATTENDANCE
On the OVERVIEW or REGISTER/TAKE COURSE tab, select the GREEN RECTANGLE, TAKE COURSE to begin.
Complete the Pretest and select NEXT in the bottom right corner of the screen. Use the NEXT button for best results.
The PowerPoint handout will be available for download.
After downloading the handout, select NEXT to begin and watch the one hour video.
You may need to select play for the video to begin.
After the video follow the prompts to complete the posttest, evaluation and attestation of credit.
Once you have completed all the components of the Course Progress bar, the certificate will be immediately downloadable.
There is no commercial support for this activity.
Questions? Look at our FAQ’s at https://cme.sheppardpratt.org/content/faq or Email email@example.com
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit